LINCOLN, Neb. – Nebraska will receive almost $3.2 million as part of a $515 million settlement with a drug company accused of misconduct.
The settlement with Bristol-Myers Squibb and its former subsidiary, Apothecon Inc., was announced Tuesday. In addition to Nebraska, it includes the federal government, 42 other states and the District of Columbia.
Attorney General Jon Bruning says the settlement addresses allegations that the New York-based drug developer reported inflated prices for drugs to Medicaid and other federal health programs and misreported sale prices for an antidepressant, among other things.
The money reimburses excessive amounts paid by Medicaid programs as a result of the misconduct.